TY - JOUR
T1 - Emetine myopathy in a patient with an eating disorder
AU - Thyagarajan, D.
AU - Day, B. J.
AU - Wodak, J.
AU - Gilligan, B.
AU - Dennett, X.
PY - 1993/12/1
Y1 - 1993/12/1
N2 - Objective: To alert physicians to the dangers of a readily available, nonprescription drug by describing the clinical and pathological features of myopathy due to chronic poisoning with ipecac syrup in a patient with an eating disorder. Clinical features: A 27-year-old woman presented in 1991 with a right foot drop, followed a few months later by progressive severe neck and limb weakness associated with dysphagia, faecal incontinence and diffuse body ache. It emerged that she had been consuming increasing quantities of ipecac syrup (up to 200 mL per week) for three months to induce vomiting and weight loss. The serum creatine kinase activity was slightly elevated and electromyographic examination results were in keeping with a necrotising proximal myopathic process. Muscle biopsy showed vacuolar degeneration with myofibrilolysis and fine cytoplasmic body formation consistent with a diagnosis of emetine myopathy. Intervention and outcome: The patient was advised to stop taking ipecac and observed for the next few months. The symptoms resolved gradually and strength returned to normal in four months. Conclusion: Chronic emetine toxicity, with its potentially catastrophic consequences, should be remembered in the evaluation of neuromuscular symptoms in young women, in whom eating disorders are common and often unrecognised.
AB - Objective: To alert physicians to the dangers of a readily available, nonprescription drug by describing the clinical and pathological features of myopathy due to chronic poisoning with ipecac syrup in a patient with an eating disorder. Clinical features: A 27-year-old woman presented in 1991 with a right foot drop, followed a few months later by progressive severe neck and limb weakness associated with dysphagia, faecal incontinence and diffuse body ache. It emerged that she had been consuming increasing quantities of ipecac syrup (up to 200 mL per week) for three months to induce vomiting and weight loss. The serum creatine kinase activity was slightly elevated and electromyographic examination results were in keeping with a necrotising proximal myopathic process. Muscle biopsy showed vacuolar degeneration with myofibrilolysis and fine cytoplasmic body formation consistent with a diagnosis of emetine myopathy. Intervention and outcome: The patient was advised to stop taking ipecac and observed for the next few months. The symptoms resolved gradually and strength returned to normal in four months. Conclusion: Chronic emetine toxicity, with its potentially catastrophic consequences, should be remembered in the evaluation of neuromuscular symptoms in young women, in whom eating disorders are common and often unrecognised.
UR - http://www.scopus.com/inward/record.url?scp=0027771530&partnerID=8YFLogxK
U2 - 10.5694/j.1326-5377.1993.tb141340.x
DO - 10.5694/j.1326-5377.1993.tb141340.x
M3 - Article
C2 - 8264462
AN - SCOPUS:0027771530
SN - 0025-729X
VL - 159
SP - 757
EP - 760
JO - The Medical Journal of Australia
JF - The Medical Journal of Australia
IS - 11-12
ER -